These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18234303)

  • 21. An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer.
    Markman M
    Cancer J; 2009; 15(2):105-9. PubMed ID: 19390303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
    Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
    Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination chemotherapy in advanced ovarian carcinoma.
    Hochster H
    J Clin Oncol; 1986 Jul; 4(7):1148. PubMed ID: 3723169
    [No Abstract]   [Full Text] [Related]  

  • 24. The future of targeted therapies in ovarian cancer.
    Banerjee S; Gore M
    Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The place of chemotherapy in the management of advanced ovarian carcinoma.
    Fennelly JJ
    J Ir Med Assoc; 1968 May; 61(371):165-71. PubMed ID: 5658600
    [No Abstract]   [Full Text] [Related]  

  • 26. Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy?
    Markman M
    J Clin Oncol; 2007 Aug; 25(23):3554; author reply 3557-8. PubMed ID: 17687167
    [No Abstract]   [Full Text] [Related]  

  • 27. Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report.
    Camci C; Sevinc A; Aslan Y; Kalender ME; Buyukberber S
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):745-8. PubMed ID: 18504578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy for ovarian cancer.
    Boronow RC; Bell WN
    J Miss State Med Assoc; 1968 Nov; 9(11):515-9. PubMed ID: 5722884
    [No Abstract]   [Full Text] [Related]  

  • 29. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study.
    Atmaca A; Al-Batran SE; Neumann A; Kolassa Y; Jäger D; Knuth A; Jäger E
    Gynecol Oncol; 2009 Feb; 112(2):384-8. PubMed ID: 19059635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Changes in the serum protein pattern after antiblastic chemotherapy of ovarian carcinoma in advanced stage].
    Gilardi G; Vertova A
    Minerva Ginecol; 1967 Aug; 19(16):799-801. PubMed ID: 5605080
    [No Abstract]   [Full Text] [Related]  

  • 31. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.
    Braly P; Nicodemus CF; Chu C; Collins Y; Edwards R; Gordon A; McGuire W; Schoonmaker C; Whiteside T; Smith LM; Method M
    J Immunother; 2009 Jan; 32(1):54-65. PubMed ID: 19307994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advanced cancer of the ovary: intraperitoneal chemotherapy as a new therapeutical option.
    Fiorentini G; Filippeschi M; Turrisi G; Mambrini A; Giannessi PG; D'Alessandro M; Rossi S; Dentico P; Guadagni S; Cantore M; Madrigali A
    In Vivo; 2009; 23(2):317-21. PubMed ID: 19414421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Combined chemotherapy of neglected form of ovarian cancer].
    Baksheeva AO
    Pediatr Akus Ginekol; 1965; 1():37-9. PubMed ID: 5879371
    [No Abstract]   [Full Text] [Related]  

  • 34. [Ovarian cancer and its chemotherapy].
    Kajka V; Musil J; Kraus I; Tikovská L
    Cesk Gynekol; 1971 Sep; 36(7):427-9. PubMed ID: 5110663
    [No Abstract]   [Full Text] [Related]  

  • 35. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical evaluation of the effect of chemotherapy in ovarian neoplasms].
    Uher M; Slot E
    Cesk Gynekol; 1971 Sep; 36(7):433-4. PubMed ID: 5110666
    [No Abstract]   [Full Text] [Related]  

  • 37. Update on in vitro testing on new drugs in ovarian cancer and melanoma.
    Salmon SE; Meyskens FL; Alberts DS; Soehnlen B; Young L
    Cancer Treat Rep; 1981; 65(5-6):532-3. PubMed ID: 7195308
    [No Abstract]   [Full Text] [Related]  

  • 38. Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer.
    Zeimet AG; Reimer D; Radl AC; Reinthaller A; Schauer C; Petru E; Concin N; Braun S; Marth C
    Anticancer Res; 2009 Jul; 29(7):2803-8. PubMed ID: 19596965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epithelial ovarian cancer: Does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance?
    Larsen E; Blaakaer J
    Acta Obstet Gynecol Scand; 2009; 88(4):373-7. PubMed ID: 19253061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The present status of cancer chemotherapy.
    Mullins F; Moore C
    J Ky Med Assoc; 1968 Mar; 66(3):255-9. PubMed ID: 5689027
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.